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Although all types of diabetes result in hyperglycemia, the pathophysiology of each
type of diabetes is different. These guidelines summarize available data speciﬁc to
the comprehensive care of youth with type 2 diabetes. The objective is to enrich
the recognition of type 2 diabetes in youth, its risk factors, its pathophysiology,
its management, and the prevention of associated complications.
PATHOPHYSIOLOGY
Glucose homeostasis is maintained by a balance between insulin secretion from the
pancreaticb-cells and sensitivity to insulin in skeletalmuscle, adipose tissue, and liver
(1). When insulin sensitivity declines, insulin secretion must increase to maintain
glucose tolerance, and, in most youth, decreased insulin sensitivity due to puberty
and/or obesity is compensated by increased insulin secretion. However, whenb-cells
cannot secrete sufﬁcient insulin to compensate for insulin resistance, abnormalities
in glucose homeostasis ensue, potentially progressing to prediabetes and type 2
diabetes as b-cell function deteriorates further (2–9). The relationship between
b-cell function and insulin sensitivity in adults and youth has been demonstrated
to be a hyperbolic function and can be described mathematically as the product of
insulin sensitivity and b-cell function, called the disposition index (DI) (1). The DI
essentially expresses the amount of insulin being secreted relative to the degree
of insulin resistance and is a constant for a given degree of glucose tolerance in any
one individual.
Overweight and obesity are major acquired contributors to the development of
insulin resistance, particularly in the face of the physiologic insulin resistance
characteristic of puberty. Robust pancreatic b-cell compensatory insulin secretion
maintains normal glucose homeostasis. However, in adolescents with obesity who
develop type 2 diabetes, there is severe peripheral and hepatic insulin resistance, with
;50% lower peripheral insulin sensitivity than peers with obesity without diabetes,
along with increased fasting hepatic glucose production and inadequate ﬁrst- and
second-phase insulin secretion, resulting in ;85% lower DI (2). Additional abnor-
malities in youth with type 2 diabetes include impaired glucose sensitivity of insulin
secretion, lower serum adiponectin concentrations, and reduced incretin effect
(3,9–13). While upregulation of a-cell function with hyperglucagonemia has been
implicated in the pathophysiology of type 2 diabetes in adults (14,15), there are
limited data in youth with type 2 diabetes, with studies showing either hyper-
glucagonemia or no difference from control subjects without diabetes (3,11,16,17).
Cross-sectional and longitudinal studies in youth with obesity along the spectrum of
glycemia from normoglycemia to prediabetes to type 2 diabetes show, as in adults,
that b-cell failure with declining insulin secretion relative to insulin sensitivity results
in prediabetes and type 2 diabetes in high-risk youth (5–9,18–21). Importantly,
however, prior to reaching the American Diabetes Association (ADA)-deﬁned fast-
ing and oral glucose tolerance test (OGTT)-stimulated glycemic cut points for the
diagnosis of prediabetes, youth, like adults, already demonstrate declining b-cell
function relative to insulin sensitivity (6–8). Also, youth with A1C in the at-risk/
prediabetes category ($5.7 to ,6.5%) demonstrate impaired b-cell function
compared with those with A1C ,5.7% (22). A combination of obesity, genetics,
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the hormonal milieu, incretins and/or
their effect, and metabolic alterations,
such as glucotoxicity and/or lipotoxicity,
are likely to contribute to deteriorating
b-cell function against the backdrop of
insulin resistance, eventually culminating
in prediabetes and type 2 diabetes in at-
risk youth. Based on the baseline data
from the Restoring Insulin Secretion
(RISE) study (23,24), there appear to
be important differences in insulin sensi-
tivity and b-cell function between youth
and adults with similar degrees of dys-
glycemia, including greater insulin resis-
tance for any degree of adiposity and
greater insulin secretion for any degree
of insulin resistance in youth compared
with adults.
RISK, SCREENING, AND DIAGNOSIS
Risk Factors
Nonmodiﬁable risk factors for youth-
onset type 2 diabetes include genetics/
epigenetics, manifested as a strong fam-
ily history of type 2 diabetes in ﬁrst- or
second-degree relatives; being the off-
spring of a pregnancy complicated by
gestational diabetes mellitus (GDM); mi-
nority race/ethnicity; and physiologic
insulin resistance of puberty. Metabolic
evidence of genetic susceptibility can
be detected in the ﬁrst decade of life,
manifested as impaired insulin sensitivity
and reduced insulin secretion in other-
wise healthy youth with a family history
of type 2 diabetes (25). This genetic sus-
ceptibility, when combined with environ-
mental factors conducive to obesity and
a sedentary lifestyle, may ultimately
translate to type 2 diabetes. Indeed, in
a study of youth with obesity, a genetic
risk score for b-cell dysfunction from
ﬁve single nucleotide polymorphisms
was associated with a higher chance of
prediabetes and type 2 diabetes (26).
Dozens of speciﬁc genetic variants linked
to type 2 diabetes have been identiﬁed
in adults (27,28), but these only account
for about 10% of its heritability (29,30).
Particular genetic variants that predis-
pose to diabetes in youth have been
identiﬁed in Oji-Cree Native Canadians
(31) and African American youth (32),
but information in other populations is
only now emerging.
Evidence from both animal and hu-
man studies suggests that maternal obe-
sity and GDM contribute to obesity and
type 2 diabetes in youth (33,34). In the
Treatment Options for Type 2 Diabetes
in Adolescents and Youth (TODAY)
cohort, one-third were born after a preg-
nancy complicated by preexisting diabe-
tes or GDM (35). In the SEARCH for
Diabetes in Youth (SEARCH) study, a
population-based study of the epide-
miology of type 1 and type 2 diabetes
in youth in the U.S., exposure to mater-
nal GDM or pregestational diabetes and
maternal obesity were independently
associated with type 2 diabetes in ado-
lescents, with intrauterine exposure to
these two risk factors present in 47.2%
of type 2 diabetes in the cohort (36).
Age of onset of type 2 diabetes was also
younger in those exposed to diabetes
during gestation.
Incidence and prevalence of type 2
diabetes are highest among youth from
a minority race/ethnicity (37), likely as
a consequence of many factors, includ-
ing genetics, metabolic characteristics,
cultural/environmental inﬂuences, and
quality of and access to health care.
Several studies have demonstrated sig-
niﬁcant differences by race/ethnicity in
insulin sensitivity and secretion that
might heighten the risk of type2diabetes
(38–42).
Type 2 diabetes typically occurs in
adolescents at midpuberty (for example,
the mean age of diagnosis was 14 years
in the TODAY study) (43), most likely
precipitated by the physiologic, but
transient, pubertal insulin resistance
aggravating the preexisting metabolic
challenges of obesity. Cross-sectional and
longitudinal studies show that insulin
sensitivity declines by 25–30% as youth
transition from prepuberty to puberty
(44–46). In the presence of normally func-
tioning b-cells, puberty-related insulin
resistance is compensated by increased
insulin secretion/hyperinsulinemia, such
that DI remains normal. In youthwho are
predisposed to develop prediabetes
and/or type 2 diabetes,b-cell compensa-
tion is inadequate with progressive de-
cline in the DI, ultimately resulting in
dysglycemia (46,47).
In youth-onset type 2 diabetes, the
major modiﬁable risk factors are obesity
and lifestyle habits of excess nutritional
intake, low physical activity, and in-
creased sedentary behaviors with de-
creased energy expenditure, resulting
in the surplus of energy being stored
as body fat. Other potentially modiﬁable
risk factors for type 2 diabetes in ado-
lescents and young adults include chronic
stress and/or depressed mood (48,49)
and sleep-related disorders (50–52).
Risk Assessment and Diagnostic
Criteria
Recommendations
c Risk-based screening for prediabe-
tes and/or type 2 diabetes should
be considered after the onset of
puberty or after 10 years of age,
whichever occurs earlier, in chil-
dren and adolescents who are over-
weight (BMI $85th percentile) or
obese (BMI $95th percentile) and
who have one or more additional
risk factors for diabetes (see Table 1
for evidence grading).
c If tests are normal, repeat testing
at a minimum of 3-year intervals E,
or more frequently if BMI is in-
creasing. C
c Fasting plasma glucose, 2-h plasma
glucose after 75-gOGTT, orA1C can
be used to test for prediabetes or
diabetes. B
Risk-based screening for prediabetes
and/or type 2 diabetes is timed after
the onset of puberty or after 10 years of
age, whichever occurs earlier, because
the majority of youth-onset type 2 di-
abetes occurs during puberty, as stated
above, and rarely inprepubertal children.
However, some youth with obesity may
have earlier onset of puberty than usual,
necessitating screening before 10 years
of age. In addition, in North America
almost all youth with type 2 diabetes
are overweight/obese, hence the re-
commendation to screen youth with
overweight/obesity. In other parts of the
world where youth with type 2 diabetes
are not necessarily overweight and/or
obese, clinical judgment should guide
whom to screen. Although there is no
robust evidence-based rationale for the
proposed frequency of testing, increas-
ing BMI has been shown to be a predic-
tor of deteriorating glycemia and
progression to type 2 diabetes (21).
Therefore, clinicians caring for youth
with overweight/obesity with continued
increase in their BMI should be aware of
the need for more frequent screening.
The laboratory glycemia-based diag-
nostic criteria for diabetes and predia-
betes are the same for youth and adults,
regardless of type of diabetes (Table
2) (53). However, these criteria are
extrapolated from adults, and the
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epidemiological studies that formed the
basis for both glucose and A1C deﬁnitions
of diabetes did not include pediatric
populations. Therefore, the exact rele-
vance of these deﬁnitions for pediatric
populations remains unclear until more
data become available.
The A1C test is universally available
and can be performed any time of the day
without need for fasting. However, sev-
eral studies have questioned its validity in
the pediatric population because of poor
sensitivity for identifying children with
dysglycemia and underestimation of the
prevalence of prediabetes and diabetes
(54–56). Fasting and OGTT criteria have
not been validated in youth, either.
Studies using continuous glucose mon-
itoring (CGM) in youth with obesity dem-
onstrated that A1C and OGTT are equally
effective at identifying glycemic abnor-
malities on CGM, but the glycemic pat-
terns differ (57); abnormal A1C was
associated with higher overall and night-
time average glucose on CGM, while
abnormal OGTT was associated with
more time spent above the normal glu-
cose range during the day. Institution of
A1C screening in a large primary care
network increased provider adherence
to screening recommendations com-
pared with OGTT screening while iden-
tifying the same prevalence of type 2
diabetes (58). Furthermore, in this
cohort, the progression to clinically
conﬁrmed diabetes was substantially
more likely for those with A1C .6%
(18.4%) than for those with levels 5.7–
6.0% (1.3%). Therefore, screening with
fasting glucose, OGTT, or A1C is an
acceptable approach but should be
based on sound clinical judgment, rec-
ognition of the strengths and weak-
nesses of each test, and the facilities and
resources available.
Conﬁrming Diabetes Type
Recommendations
c Children and adolescents with
overweight/obesity in whom the
diagnosis of type2diabetes is being
considered should have a panel of
pancreatic autoantibodies tested
to exclude the possibility of auto-
immune type 1 diabetes. B
c Genetic evaluation to exclude
monogenic diabetes should also
be based on clinical characteristics
and presentation. B
As stated above, youth with type 2 di-
abetes in the U.S. are characteristically
overweight and/or obese, in mid- to late
puberty, with overrepresentation of mi-
nority ethnic/racial groups and females
(4,43,59). The clinical presentation varies
widely from asymptomatic or minimally
symptomatic, diagnosed incidentally
during routine laboratory testing, to a
severe presentation with symptomatic
hyperglycemia, weight loss, metabolic
decompensation, diabetic ketoacidosis
(DKA), or hyperglycemic hyperosmolar
nonketotic (HHNK) syndrome (4).
Obesity is a consistent feature of
youth-onset type 2 diabetes in the
U.S. However, because of the escalating
rates of obesity in the general popula-
tion, children with both type 1 diabetes
and monogenic diabetes are also more
likely to be overweight/obese than in the
past (60), making the clinical distinction
between type 2 diabetes and obese
type 1 or monogenic diabetes difﬁcult.
This was illustrated in the TODAY study
in which, of the 1,206 youth clinically
diagnosed with type 2 diabetes and
screened for circulating GAD65 and
IA2 antibodies, 118 (9.8%)were antibody
positive (Ab1) (61). Even though these
Ab1 individuals had clinical character-
istics that overlapped with the antibody-
negative (Ab2) youth, they were less
likely to be obese, have features of
metabolic syndrome, have a family his-
tory of diabetes, be female, or be from a
minority race/ethnicity, indicating a phe-
notype more similar to their peers with
type 1 diabetes. Pathophysiologically,
Table 1—Risk-based screening for type 2 diabetes or prediabetes in asymptomatic
children and adolescents* in a clinical setting
Criteria
Testing shouldbe considered in youth*whoareoverweight ($85%)or obese ($95%)A andwho
have one or more additional risk factors based on the strength of their association with
diabetes:
c Maternal history of diabetes or GDM during the child’s gestation A
c Family history of type 2 diabetes in ﬁrst- or second-degree relative A
c Race/ethnicity (Native American, African American, Latino, Asian American, Paciﬁc
Islander) A
c Signs of insulin resistance or conditions associated with insulin resistance (acanthosis
nigricans, hypertension, dyslipidemia, polycystic ovary syndrome, or small-for-gestational-
age birth weight) B
*After the onset of puberty or after 10 years of age, whichever occurs earlier.
Table 2—Criteria for the diagnosis of prediabetes and diabetes
Prediabetes
A1C5.7%to,6.5% (39 to,48mmol/mol). The test shouldbeperformed in a laboratoryusing
a method that is NGSP certiﬁed and standardized to the DCCT assay.
IFG: fasting glucose $100 but ,126 mg/dL ($5.6 but ,7.0 mmol/L).
IGT: 2-h plasma glucose$140 but,200mg/dL ($7.8 but,11.1mmol/L) during an OGTT. The
test should be performed as described by the World Health Organization, using a glucose load
containing the equivalent of 1.75 mg/kg (max 75 g) anhydrous glucose dissolved in water.*
Diabetes
A1C$6.5% ($48 mmol/mol). The test should be performed in a laboratory using a method
that is NGSP certiﬁed and standardized to the DCCT assay.*
OR
FPG $126 mg/dL (7.0 mmol/L). Fasting is deﬁned as no caloric intake for at least 8 h.*
OR
2-hplasmaglucose$200mg/dL (11.1mmol/L) during anOGTT. The test shouldbeperformed
as described by the World Health Organization, using a glucose load containing the
equivalent of 1.75 mg/kg (max 75 g) anhydrous glucose dissolved in water*
OR
In a patientwith classic symptoms of hyperglycemia or hyperglycemic crisis, a randomplasma
glucose .200 mg/dL (11.1 mmol/L).
FPG, fasting plasma glucose; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; max,
maximum. *In the absence of unequivocal hyperglycemia, result should be conﬁrmed by
repeat testing.
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Ab2 youth with obesity are more insulin
resistant than Ab1 youth with obesity,
while Ab1 youth have more severe in-
sulin deﬁciency (61–64). Fasting and
stimulated C-peptide are signiﬁcantly
lower in Ab1 youth with obesity and
diabetes, though with appreciable over-
lap (63). Moreover, Ab2 youth are more
likely to exhibit features of themetabolic
syndrome (elevated systolic blood pres-
sure and ALT), while Ab1 youth have
signiﬁcantly more frequent ketonuria at
initial presentation (61,64). The reported
rates of positive pancreatic autoanti-
bodies in youth clinically diagnosed with
type 2 diabetes vary from 10% to 75%
(4,62), likely depending on the ratio of
type 1 and type 2 diabetes in the pop-
ulation. The clinical distinction between
youth with type 2 diabetes and youth
with obesity and type 1 or monogenic
diabetes is further blurred because youth
with type 2 diabetes often present with
some degree of ketosis, including DKA
(65).
The distinction between these forms
of diabetes in youth with obesity has
important implications for treatment
(66), since Ab1 youth present more
like individuals with type 1 diabetes,
progressing to insulin requirement
more rapidly (61), and are at risk for
other autoimmune disorders. Therefore,
measurement of pancreatic autoanti-
bodies is recommended in all youth
with clinical characteristics of type 2 di-
abetes. This testing should include
GAD65 and IA2 antibodies, along with
insulin autoantibody in individuals who
have not yet been exposed to exogenous
insulin. The beneﬁt of measurement of
ZnT8 antibody in individuals with phe-
notypic type 2 diabetes is not yet clear.
We further recommend that antibod-
ies be measured in a laboratory aligned
with the National Institute of Diabetes
and Digestive and Kidney Diseases
(NIDDK) Pancreatic Autoantibody Stan-
dardization Program because currently
available commercial assays may not be
sufﬁciently sensitive or speciﬁc. How-
ever, in all cases, clinical judgment and
the presence of other risk factors for
type 1 diabetes or type 2 diabetes should
be considered in making the diagnosis,
and the health care team should remain
open to reconsidering the initial diagno-
sis. Since 4.5–8.0% of youth with clinical
features suggestive of type 2 diabetes
have been found to have monogenic
diabetes, genetic testing for monogenic
forms of diabetes should be considered
as well (67–69).
GLYCEMIC TARGETS
Recommendations
c A1C should be measured every
3 months. E
c A reasonable A1C goal for most
children and adolescents with
type 2 diabetes treated with oral
agents alone is ,7%. More strin-
gent A1C goals (such as ,6.5%)
may be appropriate for selected
individual patients if they can be
achieved without signiﬁcant hypo-
glycemia or other adverse effects
of treatment. Appropriate patients
might include those with short
duration of diabetes and lesser
degrees of b-cell dysfunction and
patients treated with lifestyle or
metformin only who achieve sig-
niﬁcant weight improvement. E
c A1C targets for youth on insulin
should be individualized, taking
into account the relatively low
rate of hypoglycemia in youth-
onset type 2 diabetes. E
c Home self-monitoring of blood glu-
cose (SMBG) regimens should be
individualized, taking into consid-
eration the pharmacologic treat-
ment of the patient. E
Previous target A1C guidelines by the
ADA and the International Society for
Pediatric and Adolescent Diabetes for
youth with type 2 diabetes ranged
from ,6.5% to ,7.0% (70,71) and
,7.5% (72), mostly based on expert
opinion and extrapolated from youth
with type 1 diabetes and adults with
type 2 diabetes. However, accumulating
evidence provides support for more
appropriate goals. The TODAY study
showed that hypoglycemia is rare in
adolescents with type 2 diabetes, even
with insulin therapy (73), suggesting that
more stringent A1C targets are accept-
able. Also in TODAY, individuals with an
A1C of .6.3% after 3 months of met-
formin or an increasing A1C, even in the
nondiabetes range (74), had a substan-
tially increased risk for loss of glycemic
control, likely reﬂecting a greater de-
gree of b-cell dysfunction (75,76). Fur-
thermore, individuals with youth-onset
type 2 diabetes have high rates of
complications (77–79), many of which
are associated with poor glycemic con-
trol, and rapid deterioration with in-
creasing A1C. Finally, youth with type 2
diabetes can be expected to have
long disease duration and, therefore,
continued risk for accumulation of
glycemia-related complications. Taken
together, this evidence suggests that
a more stringent A1C target can and
should be attained in youth with type 2
diabetes.
The evidence is insufﬁcient regarding
the value of SMBG and how often test-
ing should be performed by youth with
type 2 diabetes not on insulin therapy.
Until such data become available, the
frequency of SMBG should be individu-
alized, taking into account patient and
family burden, the value of the informa-
tion obtained and how it will be used to
adjust therapy, and the associated hy-
poglycemia risk.
LIFESTYLE MANAGEMENT
Diabetes Education and
Self-Management Skills
Recommendation
c All youth with type 2 diabetes and
their families should receive compre-
hensive diabetes self-management
education/support that is speciﬁc
to youthwith type 2 diabetes and is
culturally competent. B
It has been well established that di-
abetes education is necessary, but not
sufﬁcient, to enhance self-management
in people with diabetes (80,81). The
majority of these studies, however, fo-
cused on adults with type 2 diabetes
and/or youth with type 1 diabetes. Since
the population of youth with type 2
diabetes is more likely to be of minority
ethnic/racial background than thosewith
type 1 diabetes, and materials devel-
oped for adults may not address issues
of development in youth, culturally
appropriate programs speciﬁc to youth
with type 2 diabetes and their families
are necessary. Unfortunately, there are
no randomized clinical trials of educa-
tion and support programs for youth
with type 2 diabetes. Nonetheless, de-
scriptive reports suggest that programs
that focus on building knowledge and
skills appropriate to this population are
important in ensuring adequate self-
management.
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In the TODAY trial (81), the diabetes
education program included content
about type 2 diabetes physiology and
treatment, building skills of healthy eat-
ing habits, carbohydrate counting, por-
tion sizes, reading food labels, glucose
monitoring, andketone testing, aswell as
problem solving, risk reduction, and liv-
ing with diabetes. Full mastery of the
program was achieved in an average of
5.5 90-min sessions. Factors associated
with shorter time to mastery included
more recent diagnosis and not having to
use a translator, while sex, primary lan-
guage of the youth and family, individual
versus group sessions, or site of delivery
were not. These program materials are
available from the ADA as “Be Healthy
Today” (82). Given the lack of clinical
trials of various educational approaches,
it is unclear that this program is superior
to other approaches. Nonetheless, the
program provides effective, engaging
materials for youth with type 2 diabetes
that were designed speciﬁcally for this
population. Until comparative trials of
various approaches are completed, di-
abetes education using these materials
is appropriate (83).
Psychosocial Factors
Recommendations
c Providers should assess social con-
text, including potential food in-
security, housing stability, and
ﬁnancial barriers, and apply that
information to treatment deci-
sions. E
c Use patient-appropriate standard-
ized and validated tools to assess
diabetes distress and mental/
behavioral health in youth with
type 2 diabetes, with attention
to symptoms of depression and
disordered eating behaviors, and
refer to specialty care when indi-
cated. B
c When choosing glucose-lowering
or other medications for youth
with overweight/obesity and type
2 diabetes, consider medication
adherence and treatment effects
on weight. E
c Starting at puberty, preconception
counseling should be incorporated
into routine diabetes clinic visits
for all females of childbearing po-
tential. A
c Patients should be screened for
smoking and alcohol use at diag-
nosis and regularly thereafter. C
The ADA position statement on the pro-
vision of psychosocial care for people
living with diabetes recognizes the pro-
found inﬂuence of psychosocial factors
on health outcomes and well-being (84).
The recommendations herein are con-
sistent with those outlined in that posi-
tion statement, an important resource
for more detailed information about life-
course issues and assessment of psycho-
social comorbidities.
Most youthwith type 2 diabetes come
from racial and ethnic minority groups,
have low socioeconomic status, and
have a family history of diabetes
(37,85,86). Families often experience
multiple stressors including food insecu-
rity, employment and housing instability,
and difﬁculties with access to treatment;
youth also may have been exposed to
early adversity, which has been shown to
affect health over time (87). Providers
should personalize approaches to diabe-
tes management to minimize barriers to
care, enhance adherence, and maximize
response to treatment by taking into
consideration the sociocultural context
of the patient and their family.
Youth with type 1 diabetes have high
rates of diabetes distress and psychiatric
symptoms and diagnoses (in particular,
depression and disordered eating behav-
iors) necessitating ongoing surveillance
of mental and behavioral health. Evi-
dence about psychiatric disorders and
symptoms in youth with type 2 diabetes
is limited (88–92), but given the socio-
cultural context and the medical burden,
as well as preexisting obesity-associated
comorbidities together with type 2 di-
abetes, ongoing surveillance of mental
health/behavioral health is also indicated
in youth with type 2 diabetes.
Symptoms of depression and disor-
dered eating are common in youth with
type 2 diabetes and associated with
poorer glycemic control (89). The prev-
alence of clinically signiﬁcant symptoms
of depression among youth with type 2
diabetes was reported to be 8.6% in the
SEARCH cohort of youth with type 1 and
type 2 diabetes (89) and 14.8% in the
TODAY cohort of youth with type 2 di-
abetes (93). In addition, more than 25%
of females and males in the SEARCH
cohort of youth with type 2 diabetes
reported symptoms of disordered eating
behaviors, such as skipping insulin, vom-
iting, and using diet pills or laxatives,
and these behaviors were associated
with poorer glycemic control in females
(89). Binge eating rates in the TODAY
cohort were high (26%) and were asso-
ciated withmore severe obesity, psycho-
logical symptoms of disordered eating,
and symptoms of depression (94).
More research is needed to evaluate
rates of diagnosable psychiatric disor-
ders, trauma, victimization, and psycho-
tropic drug use in youth with type 2
diabetes. It also is important to elucidate
the relationships among obesity, psychi-
atric disorders, andmedication regimens
because many of the drugs prescribed
for diabetes and psychiatric disorders
are associated with weight gain and in-
creased concerns about eating, shape,
and weight (95,96).
Finally, in accord with the ADA’s Stan-
dards ofMedical Care in Diabetesd2018
(97), preconception counseling should
be provided starting at puberty for all
girls of childbearing potential in order to
increase understanding of risk related
to diabetes and improve health prior to
conception. In the TODAY study (98),
despite counseling on pregnancy reduc-
tion designed speciﬁcally for youth with
type 2 diabetes, 10.2% of the females in
the cohort became pregnant over an
average of 3.8 years of study participa-
tion. Of note, 26.4% of pregnancies
ended in a miscarriage, stillbirth, or in-
trauterine death, and 20.5% of the live-
born infants had a major congenital
anomaly. These data conﬁrm the impor-
tance of educating young women with
type 2 diabetes to time their pregnancies
to reduce risks to themselves and their
offspring. More research regarding preg-
nancy outcomes in youth with type 2
diabetes is needed.
Lifestyle Modiﬁcation, Weight
Management, Exercise, and Nutrition
Recommendations
c Youthwithoverweight/obesity and
type 2 diabetes and their families
should be provided with develop-
mentally and culturally appropriate
comprehensive lifestyle programs
that are integrated with diabetes
management aiming to achieve 7–
10% decrease in excess weight. C
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c Given the necessity of long-term
weight control and lifestyle man-
agement for children and adoles-
cents with type 2 diabetes, lifestyle
intervention should be based on a
chronic care model and offered in
the context of diabetes care. E
c Youth with diabetes, like all chil-
dren, should be encouraged to
participate in at least 30–60 min
of moderate to vigorous physical
activity at least 5 days per week
(and strength training on at least
3 days per week) B and should be
encouraged to decrease sedentary
behavior. C
c Nutrition for youth with type 2
diabetes, like all children, should
focus on healthy eating patterns
that emphasize consumption of
nutrient-dense, high-quality foods
and decrease consumption of
calorie-dense, nutrient-poor foods,
particularly sugar-added bever-
ages. B
c The utility of pharmacotherapy for
weight reduction in youth with
type 2 diabetes remains limited
in the absence of approved, effec-
tive, and safe medications and the
lack of clinical trials in youth with
type 2 diabetes. B
Lifestyle modiﬁcation programs that
incorporate evidence-informed behav-
ioral strategies to promote changes in
diet and physical activity (99) are a cor-
nerstone of treatment for adults with
type 2 diabetes because the resulting
reductions of 5–7% of initial body weight
are associated with improvements in
blood glucose levels and other risk pa-
rameters. Much less is known about the
impact of lifestyle interventions in youth
with type 2 diabetes, although 90% are
overweight or obese. Family-based be-
havioral weight management programs
in school-aged children without diabetes
have a modest, but positive, impact on
weight and cardiometabolic risk factors
but are less effective in adolescents and
children with more severe obesity (100–
102). Intensive weight management,
when compared with usual treatment,
can have sustained beneﬁts over a 2-
year period for ethnically and racially di-
verse inner-city children and adolescents
with an average BMI .35 (102,103).
Although BMI changes in treated youth
were modest (103), those who re-
ceived usual care showed increases in
BMI over the period of observation,
while the intervention group had con-
tinued improvements in body com-
position and insulin resistance relative
to those who did not receive weight
management.
The most pertinent evidence regard-
ing the impact of lifestyle interventions
for youth with type 2 diabetes comes
from the TODAY study (104), where the
goal was to achieve 7–10% decrease in
percent overweight. The addition of life-
style intervention to metformin mono-
therapy was not associated with durable
metabolic control beyond that of met-
formin alone. Youth receivingmetformin
plus lifestyle intervention showed short-
term, but not sustained, weight loss and
improvements in body composition rel-
ative to those in the two other interven-
tion groups (105). While 31% of youth
who received lifestyle intervention
achieved the preplanned goal of a de-
crease of $7% in percent overweight
through 24 months of intervention, this
result did not differ signiﬁcantly from
that obtained with metformin mono-
therapy and no predictors of successful
weight loss were identiﬁed. However,
irrespective of treatment assignment,
sustained weight losses $7% of excess
body weight were associated with im-
provements in A1C, HDL, and C-peptide
(105), indicating that obesity manage-
ment remains a crucial goal.
Components of a comprehensive pe-
diatric lifestyle intervention are well es-
tablished (106,107), including those for
youth with severe obesity (108). These
include the involvement of family at a
developmentally appropriate level and
evidence-based behavioral strategies to
facilitate enduring changes in nutrition
andphysical activity. Guidelines for phys-
ical activity and nutrition are based on
those recommended by the American
Academy of Pediatrics (2007) (107) and
the Endocrine Society (2017) (106).
Youth with type 2 diabetes frequently
have severe obesity, and it is particularly
important that behavior change goals
for diet and activity incorporate step-
wise, achievable targets developed in
conjunction with the youth and family
members, as appropriate.
Youth with type 2 diabetes will face
increasing severity of obesity and diabe-
tes complications as they age (109–111).
An important ﬁrst step is to integrate
diabetes care and education, such as the
approach used in the TODAY trial, with
ongoing lifestyle intervention for obesity
management (106) to maximize the im-
pact of medical and lifestyle interven-
tions over time. Comprehensive chronic
care models have been recommended
for youthwith obesity and chronic illness
(112,113).
With the exception of orlistat, weight
loss medications are not approved for
use in youth. The Endocrine Society
guidelines for pediatric obesity (106)
review the limited evidence for effec-
tiveness of current weight-loss medica-
tions and recommends that their use be
restricted to the research setting. More
research into possible pharmacologic ap-
proaches to augment lifestyle interven-
tions and their role in type 2 diabetes in
youth is urgently needed.
PHARMACOLOGIC APPROACHES
TO GLYCEMIC MANAGEMENT
Recommendations
c Initiate pharmacologic therapy, in
addition to lifestyle therapy, at di-
agnosis of type 2 diabetes. A
c In incidentally diagnosed or meta-
bolically stable patients (A1C
,8.5% and asymptomatic), met-
formin is the initial pharmacologic
treatment of choice if renal func-
tion is normal. A
c Youth with marked hyperglycemia
(blood glucose $250 mg/dL, A1C
$8.5%) without acidosis at diag-
nosis who are symptomatic with
polyuria, polydipsia, nocturia, and/
or weight loss should be treated
initially with basal insulin while
metformin is initiated and titrated.
B
c In patients with ketosis/
ketoacidosis, treatment with sub-
cutaneous or intravenous insulin
should be initiated to rapidly cor-
rect the hyperglycemia and the
metabolic derangement. Once
acidosis is resolved, metformin
should be initiated while subcuta-
neous insulin therapy is continued.
A
c In individuals presenting with se-
vere hyperglycemia (blood glucose
$600 mg/dL), assess for HHNK
syndrome. A
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c In patients initially treated with
insulin and metformin who are
meeting glucose targets based
onhomebloodglucosemonitoring,
insulin can be tapered over 2–
6 weeks by decreasing the insulin
dose 10–30% every few days. B
c If the glycemic target is no longer
met using metformin alone, or if
contraindications or intolerable
side effects of metformin develop,
basal insulin therapy should be
initiated. B
c If the combination of metformin
plus basal insulin is ineffective at
achieving or maintaining glycemic
targets, more intensive approaches
to insulin therapy may be initiated.
E
c The use of nonapproved medica-
tions in youth with type 2 diabetes
is not recommended outside of
research trials. B
In the clinical setting, only a minority of
youth with type 2 diabetes are on lifestyle
management alone (114,115) because it
is often inadequate for achieving and
maintaining the desired level of glycemic
control and BMI improvement, with the
percentage of patients remaining on
lifestyle intervention alone declining fur-
ther by 1 year (115). Therefore, in most
cases, the addition of pharmacologic in-
tervention early in the disease is war-
ranted. As in adults, the pharmacologic
intervention should be a stepped pro-
cess. However, since onlymetformin and
insulin are currently approved for the
treatment of diabetes in patients under
18 years old, the approach in youth is
more limited.
Initial Treatment
Initial treatment of youth-onset type 2
diabetes should include metformin and/
or insulin alone or in combination, based
on the metabolic status of the patient.
Initial treatment of the youth with obe-
sity and diabetes must take into account
that diabetes type is often uncertain in
theﬁrst fewweeks of treatment owing to
overlap in presentation and that a sub-
stantial percentage of youth with type 2
diabetes will present with clinically sig-
niﬁcant ketoacidosis (65). Therefore, im-
mediate therapy should address the
hyperglycemia and associated metabolic
derangements irrespective of ultimate
diabetes type, with adjustment of ther-
apy once metabolic compensation has
been established and subsequent infor-
mation, such as antibody results, be-
comes available.
Figure 1 provides an approach to initial
treatment.
Metformin
Metformin is thepreferreddrug for initial
treatment of type 2 diabetes in adults
and youth. In the TODAY study, 48.3% of
youth with type 2 diabetes who were
Figure 1—Management of new-onset diabetes in overweight youth suspected to have type 2 diabetes based on risk factors listed in Table 1. MDI,
multiple daily injections.
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enrolled, with less than 2 years (median
8 months) of diabetes duration, main-
tained adequate glycemic control (A1C
,8.0%) on metformin alone for up to
6 years (104).However, youthweremore
likely than adults to require additional
pharmacologic treatment to meet glyce-
mic targets, with the other 51.7% of
youth on metformin requiring insulin
by 4 years, with a median time to treat-
ment failure of 11.8 months.
Asymptomatic youthwith presumptive
type 2 diabetes who present in a stable
metabolic state and have A1C ,8.5%
should be started on metformin as initial
therapy if renal function isnormal.Asymp-
tomatic patients with A1C $8.5% may
also be given an initial trial of metformin
monotherapy at the discretion of the
health care provider, especially if the
patient and family situation suggest the
promise of excellent adherence to life-
style change recommendations.
The recommended approach to met-
formin initiation is to start with a dose
of 500–1,000 mg/day and gradually es-
calate it every 1–2 weeks, depending on
patient tolerability, to the recommended
therapeutic dose of 1,000 mg b.i.d.
Slower dosage escalationmay be needed
if gastrointestinal side effects occur and,
in somecases, themaximumdosemaynot
be achievable. Extended-release metfor-
min may have fewer gastrointestinal side
effects and be more convenient for the
patient, but there are no studies in youth
comparing extended-release metformin
to the standard metformin preparation.
Metformin Plus Insulin
Youth with marked hyperglycemia (blood
glucose $250 mg/dL and/or A1C $8.5%)
without acidosis at diagnosis but who
are symptomatic with polyuria, polydip-
sia, nocturia, and/or weight loss should
be treated initially with basal insulin
while concurrently initiating and titrat-
ing metformin. In patients with ketosis/
ketoacidosis at diagnosis, treatmentwith
subcutaneous or intravenous insulin should
be initiated to rapidly correct the hyper-
glycemia and the metabolic derangement.
Once acidosis is resolved, metformin
should be initiated while subcutane-
ous insulin therapy is continued (116).
In individuals presenting with severe
hyperglycemia (blood glucose $600
mg/dL), assess for HHNK syndrome.
Once glycemic stability is achieved,
insulin may not be needed. Limited
data suggest that adolescents with
type 2 diabetes who present initially
with DKA, ketosis, or symptomatic hy-
perglycemia can be managed success-
fully with metformin alone, at least
initially after a short course of insulin
therapy to establish glycemic stability
(117). For example, in the TODAY study,
more than 90% of the subjects screened
for study participation were initially con-
trolled adequately on metformin alone
regardless of prior insulin therapy (117).
However, theseTODAYparticipantswere
frequently contacted and closely moni-
tored by the research staff, a situation
that may not be feasible in a clinical
setting. Whether or not early treatment
with insulin provides unique beneﬁts in
youth with type 2 diabetes remains ques-
tionable. The recently completed RISE
Pediatric Medication Study in youth
with obesity with impaired glucose toler-
ance or recent-onset type 2 diabetes did
not demonstrate beneﬁts of 3 months of
basal insulin glargine followed by 9
months of metformin compared with
metformin alone for 12 months in pre-
serving or restoringb-cell function (118).
It remains to be determined if longer
periods of insulin treatment may prove
beneﬁcial in preserving b-cell function.
Ongoing Therapy
When the individualized glycemic target
can no longer be met with metformin
alone, or if metformin intolerance or
renal insufﬁciency develops, insulin ther-
apy should be initiated. This can be done
alone or in combination with metformin,
unless metformin is contraindicated. Be-
cause studies indicate that adherence
with insulin therapy is a challenge in
youth with type 2 diabetes (73,119),
starting with a single daily dose of a
long-acting insulin analog (glargine
[Lantus, Basalglar, Toujeo], detemir
[Levemir], or degludec [Tresiba]) may
be preferred. Premixed insulins may be
appropriate in some circumstances.
If the combination of metformin at the
maximum tolerated dose (up to 1,000 mg
b.i.d.) plus basal insulin at a maximum
dose of 1.5 units/kg/day is ineffective at
achieving the glycemic target, medica-
tion adherence should be actively ad-
dressed. When combined metformin
and basal insulin therapy does not
achieve targets, and in the absence of
other approved drugs to treat diabetes in
youth (,18 years old), higher doses of
long-acting insulin or initiation of multi-
ple daily injections of basal and premeal
rapid-acting insulin should be consid-
ered, though adherence to the latter
may be a barrier.
Because severe insulin resistance is
characteristic of youth with type 2 di-
abetes, basal insulin doses above 1.5
units/kg/day may be required to achieve
adequate glycemic control, particularly
for those youth with elevated A1C and
glucotoxicity and youth who are in mid-
to late puberty. In these circumstances,
it may be appropriate to use more con-
centrated insulin preparations (U-300
glargine [Toujeo], U-200 Tresiba, U-200
Humalog, U-500 regular) to avoid large-
volume injections that may further di-
minish medication adherence.
The most signiﬁcant adverse effect
of insulin therapy in type 2 diabetes, as
in type 1 diabetes, is hypoglycemia. Al-
though the incidence of hypoglycemia
in youth with type 2 diabetes is low,
even with insulin therapy (73), patients
treated with insulin should be educated
about avoidance, recognition, and treat-
ment of hypoglycemia and should be
instructed on the use of glucagon for
treatment of severe hypoglycemia. Also,
since insulin may result in weight gain,
involvement of a nutritionist in patient
care and education is essential when
insulin is initiated.
Other Therapies
Other than insulin and metformin, there
are currently more than 25 medications in
10 general classes that are commercially
availableandFDA-approved for treatment
of type 2 diabetes in adults in the U.S.
(Table3). It shouldbenoted,however, that
none of these are currently approved for
use in youth (,18 years old), and while
some of these agents have undergone
or are currently undergoing pharmaco-
kinetic, pharmacodynamics, and safety/
tolerability testing in small pediatric
studies, no efﬁcacy or long-term safety
results have yet been reported in youth.
Although the TODAY study demon-
strated that the addition of rosiglitazone
to metformin improved the durability of
glycemic control (treatment failure rate
38.6% for metformin plus rosiglitazone
vs. 51.7% for metformin alone) with no
increased rate of adverse events over a
3–6 year period in youth with recent-
onset type 2 diabetes, it is premature
to recommend its widespread use in
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youth with type 2 diabetes, especially
since its use is not approved in the pe-
diatric population. Even though many
of the newer agents approved in the
adult population are promising and
may have particular beneﬁts in youn-
ger individuals with diabetes, we can-
not recommend widespread use of
these medications until additional
studies are completed. Unfortunately,
implementation and completion of
such studies have been slow and
many barriers have been identiﬁed
(111). Therefore, we recommend that
the use of these medications in youth
with type 2 diabetes be avoided outside
of research trials. However, collabo-
ration among investigators, pharma-
ceutical sponsors, and governmental
regulators is urgently needed to expand
treatment options for this population of
patients.
METABOLIC SURGERY
Recommendations
c Metabolic surgery may be consid-
ered for the treatment of adoles-
cents with type 2 diabetes who are
markedly obese (BMI .35 kg/m2)
Table 3—Drugs for treating type 2 diabetes in adults (not including insulin or insulin analogs) but not yet approved in
youth except for metformin
Drug class
Available drugs in
this class Mechanism of action Signiﬁcant adverse effects
Approved in
patients,18 years old
Biguanides Metformin Decreases insulin resistance; reduces
hepatic glucose production; increases
peripheral glucose uptake; decreases
gastrointestinal absorption of glucose
Gastrointestinal
Lactic acidosis
Yes
Sulfonylureas Glipizide
Glimepiride
Glyburide
Stimulates secretion of insulin from the
b-cell
Hypoglycemia
Weight gain
No
Meglitinides Repaglinide
Nateglinide
Stimulates glucose-dependent secretion
of insulin from the b-cell
Hypoglycemia
URI
Diarrhea
Headache
No
a-Glucosidase
inhibitors
Acarbose
Miglitol
Delays absorption of glucose by
intestines by inhibiting breakdown of
complex sugars
Flatulence
Diarrhea
Abdominal cramps
No
GLP-1 agonists Exenatide
Liraglutide
Dulaglutide
Lixisenatide
Albiglutide
Semaglutide
Incretin effect; slows gastric emptying;
enhances postprandial insulin
biosynthesis; improvesb-cell function;
decreases appetite
Acute pancreatitis
C-cell hyperplasia/ medullary
thyroid carcinoma
Nausea/vomiting
Hypoglycemia
Diarrhea
Headache
No
DPP-4 inhibitors Saxagliptin
Sitagliptin
Alogliptin
Linagliptin
Inhibits DPP-4 enzyme, reducing
endogenous GLP-1 breakdown
Acute pancreatitis
URI
UTI
Nasopharyngitis
Headache
No
Amylin analog Pramlintide Inhibits postprandial glucagon secretion;
delays gastric emptying; improves
satiety
Hypoglycemia
Nausea
Anorexia
Abdominal pain
No
Thiazolidinediones Rosiglitazone
Pioglitazone
PPAR-g inhibitor; increases insulin
sensitivity in liver,muscle, and adipose
tissue; decreases hepatic glucose
output
Edema
Weight gain
Anemia
Elevated liver enzymes
No
SGLT-2 inhibitors Canagliﬂozin
Dapagliﬂozin
Empagliﬂozin
Ertugliﬂozin
Allowsmoreglucose tobeexcreted in the
urine and hence lowers blood glucose
Euglycemic ketoacidosis
UTI
Candidal vulvovaginitis
No
Bile acid
sequestrant
Colesevelam Mechanism for glucose lowering is
unknown
Gastrointestinal (gas, nausea,
diarrhea, abdominal pain)
Weakness
Muscle pain
No
Dopamine-2
agonist
Bromocriptine
(quick release)
Modulates hypothalamic regulation of
metabolism; increases insulin
sensitivity
Nausea/vomiting
Fatigue
Dizziness
Headache
No
DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1; PPAR, peroxisome proliferator–activated receptor; SGLT2, sodium–glucose
cotransporter 2; URI, upper respiratory infection; UTI, urinary tract infection.
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and who have uncontrolled
glycemia and/or serious co-
morbidities despite lifestyle and
pharmacologic intervention. A
c Metabolic surgery should be per-
formed only by an experienced
surgeon working as part of a well-
organized and engaged multidis-
ciplinary team including surgeon,
endocrinologist, nutritionist, behav-
ioral health specialist, and nurse. A
Bariatric or metabolic surgery, includ-
ing Roux-en-Y gastric bypass, vertical
sleeve gastrectomy, laparoscopic adjust-
able gastric banding, laparoscopic
gastric plication, and biliopancreatic di-
version, has been shown to signiﬁcantly
reduce weight, BMI (120), and cardio-
vascular comorbidities (121) in adults
with obesity and is now considered a
standard component of care for adults
with morbid obesity. Metabolic surgery
is also an effective strategy for preven-
tion (122,123) and treatment of type 2
diabetes in obese and severely obese
(BMI$30 kg/m2) adults (124–129) and is
now endorsed as part of the algorithm
for treating type 2 diabetes in adults
(127).
Over the last decade, weight-loss sur-
gery has been increasingly performed in
adolescents with obesity, but the long-
term experience remains limited. The
current guidelines for metabolic sur-
gery in adolescents generally include
BMI .35 kg/m2 with signiﬁcant comor-
bidities or BMI.40 kg/m2 with or with-
out comorbidities (106,130–140). The
Endocrine Society Clinical Practice Guide-
line on Pediatric Obesity discusses bar-
iatric surgery for the management of
pediatric obesity in detail, and interested
readers can refer to it (106). Brieﬂy,
positive outcomes of metabolic surgery
have included remission of type 2 dia-
betes, improvements in glucose homeo-
stasis in youth without diabetes,
improvement in surrogate markers of
insulin sensitivity and secretion, resolu-
tion of sleep apnea, improvements in
nonalcoholic fatty liver disease (NAFLD),
and improvements in cardiovascular dis-
ease (CVD) risk factors, among others
(106,134–141). Direct comparison be-
tween the medical management of youth
with type 2 diabetes and bariatric surgery
outcome, both short- and long-term, is
very limited. A recent study compared
youth with type 2 diabetes from the
Teen-Longitudinal Assessment of Bariat-
ric Surgery (Teen-LABS) cohort who had
undergone a bariatric surgical procedure
with youth with medically treated type 2
diabetes from the TODAY cohort. Dur-
ing 2 years, A1C decreased from 6.8% to
5.5% in Teen-LABS and increased from
6.4% to 7.8% in TODAY, BMI decreased
by 29% in Teen-LABS and increased by
3.7% in TODAY, elevated blood pres-
sure decreased from 45% to 20% of par-
ticipants in Teen-LABS and increased
from 22% to 41% in TODAY, and dys-
lipidemia decreased from 72% to 24% in
Teen-LAB versus no appreciable change
in TODAY (142).
Overall, studies in both adults and
adolescents suggest that those who
undergo bariatric surgery earlier in
the course of diabetes (that is, at a
younger age or with higher baseline
b-cell function) have a higher remission
rate despite similar weight loss (143). Ini-
tial diabetes remission rates in adults
range between 40% and 70%, whereas
in adolescents the reported initial rates
are as high as 68–100% (144). The long-
term durability of these remissions is un-
known and will require longer follow-up.
Short-term and long-term complica-
tions of metabolic surgery need to be
taken into consideration. In Teen-LABS,
13% of adolescents required a second
operative procedure and another 13%
required an endoscopic procedure be-
cause of a complication (145). In the
recent Teen-LABS/TODAY comparison,
30% of the youth with diabetes under-
going surgical intervention required re-
admission and/or reoperation (142).
Postoperative nutritional complications
(vitamin B12, thiamine, and vitamin D
deﬁciency) are also prevalent. Long-term
follow-up and further research is re-
quired to better understand the mech-
anisms by which metabolic surgery
improves type 2 diabetes and the short-
term and long-term beneﬁts and risks
of this procedure in youth. Quality of
life and economic (cost-beneﬁt) analy-
ses will also be important components
of ongoing follow-up and research
(146,147).
PREVENTION AND MANAGEMENT
OF DIABETES COMPLICATIONS
Youth-onset type 2 diabetes is associ-
ated with signiﬁcant microvascular and
macrovascular risk burden and a sub-
stantial increase in the risk of cardiovas-
cular morbidity and mortality at an
earlier age than those individuals diag-
nosed later in life (148). The higher
complication risk in earlier-onset type
2 diabetes is likely to be related to
prolonged lifetime exposure to hy-
perglycemia and other atherogenic risk
factors, including insulin resistance, dys-
lipidemia, hypertension, and chronic
inﬂammation. These diabetes comorbid-
ities also appear to be higher than in
youth with type 1 diabetes despite
shorter diabetes duration and lower
A1C (149). In addition, the progression
of vascular abnormalities appears to
be more pronounced in type 2 diabe-
tes diagnosed earlier in life compared
with type 1 diabetes of similar duration,
including ischemic heart disease and
stroke (150,151).
Nephropathy
Recommendations
c Blood pressure should be mea-
sured at every visit. A
c Blood pressure should be opti-
mized to reduce risk and/or slow
the progression of diabetic kidney
disease. A
c If blood pressure is.95th percen-
tile for age, sex, and height, in-
creased emphasis should be
placed on lifestyle management
to promote weight loss. If blood
pressure remains above the 95th
percentile after 6 months, antihy-
pertensive therapy should be ini-
tiated. C
c Initial therapeutic options include
ACE inhibitors or angiotensin recep-
tor blockers. Other blood pressure–
lowering agents may be added as
needed. C
c Protein intake should be at the
recommended daily allowance of
0.8 g/kg/day. E
c Urine albumin/creatinine ratio
(UACR) should be obtained at
the time of diagnosis and annually
thereafter. An elevated UACR
(.30 mg/g creatinine) should be
conﬁrmed on two of three sam-
ples. B
c Estimated glomerular ﬁltration
rate (eGFR) should be determined
at the time of diagnosis and annu-
ally thereafter. E
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c In nonpregnant youth with diabe-
tes andhypertension, either anACE
inhibitor or an angiotensin recep-
tor blocker is recommended for
those with modestly elevated
UACR (30–299 mg/g creatinine)
D and strongly recommended for
those with UACR .300 mg/g cre-
atinine and/or eGFR,60 mL/min/
1.73 m2. E
c For those with nephropathy, con-
tinued monitoring (yearly UACR,
eGFR, serumK)mayaid in assessing
adherence and detecting progres-
sion of disease. E
c Referral to nephrology is recom-
mended in case of uncertainty of
etiology, worsening UACR, or de-
crease in eGFR. E
Diabetic kidney disease is diagnosed in
the presence of elevated albumin excre-
tion and decreased eGFR and is the
leading cause of end-stage renal disease
(152). Elevated UACR or albuminuria,
deﬁned as .30 mg/g creatinine, and
hyperﬁltration, deﬁned as an eGFR be-
tween 120 mL/min/1.73 m2 and 150
mL/min/1.73 m2 (153,154), are early ab-
normalities that indicate increased risk
of progression to diabetic kidney disease
(154,155). Overt nephropathy is deﬁned
as persistent proteinuria $500 mg/day
or UACR $300 mg/g creatinine and an
eGFR ,60 mL/min/1.73 m2.
Albuminuria and hyperﬁltration de-
tected early in youth with type 2 diabe-
tes may occur because of obesity before
the onset of diabetes (156) and can be
related to early vascular dysfunction
(157). In TODAY, theprevalence ofmicro-
albuminuria was 6.3% at randomization
(mean 7.8 months since diagnosis of
diabetes) and increased to 16.6% over
3 years (79). This coincided with pro-
gression of dyslipidemia (from 4.5% at
baseline to 11%) and hypertension (from
11.6% at baseline up to 33%) (78,79)
despite standardized therapy for these
comorbidities. The main determining
factor in albuminuria progression was
A1C, with 17% higher risk of developing
albuminuria per 1% increase in A1C (79),
consistent with ﬁndings in other studies
(149). Modiﬁable risk factors include
obesity, dyslipidemia, hypertension,
and glycemia (152). In some ethnic
groups, particularly Pima Indians and
First Nations people in Canada, the
risk of nephropathy is much higher in
youth with type 2 diabetes (158–161).
Spot UACR is generally recommended
for screening of urinary albumin excre-
tion, with an abnormal value conﬁrmed
on two of three consecutive tests ob-
tained on different days within a 3- to
6-month period. Results can be affected
by orthostatic proteinuria, marked hy-
perglycemia, exercise, menstruation,
recent intercourse, and sample contam-
ination. eGFR can be calculated from
serumcreatinine and thepatient’s height
using the Schwartz equation. However,
recent studies suggest that this under-
estimates hyperﬁltration, which is highly
prevalent in youth with type 2 diabetes,
and a combined estimation using serum
creatinine and serum cystatin C is pref-
erable when available (162).
In addition to optimizing glycemia,
control of hypertension is important
to prevent and slow the progression
of nephropathy. Therapeutic options in-
clude the use of ACE inhibitors or angio-
tensin receptor blockers (152,163–165).
If not tolerated, a calcium channel
blocker or diuretic or combination ther-
apy may be required if hypertension does
not normalize on single-agent therapy.
Neuropathy
Recommendations
c Youth with type 2 diabetes should
be screened for the presence of
neuropathy by foot examination at
diagnosis and annually. The exam-
ination should include inspection,
assessment of foot pulses, pinprick
and 10-g monoﬁlament sensation
tests, testing of vibration sensa-
tion using a 128-Hz tuning fork,
and ankle reﬂexes. C
c Prevention should focus on achiev-
ing glycemic goals. C
Diabetic neuropathy can manifest as
distal polyneuropathy (DPN), mononeu-
ropathy, and/or autonomic neuropathy.
Mononeuropathies are uncommon. DPN
is usually the earliest clinically apparent
manifestation of neuropathy in persons
with diabetes and most commonly
presents with paresthesia, numbness,
or pain in the feet. DPN generally affects
the small myelinated ﬁbers ﬁrst with
burning or stabbing pain and reduced
or absent thermal and pinprick sen-
sation. It then progresses to larger
myelinated ﬁbers with numbness, tin-
gling, and poor balance along with re-
duced or absent reﬂexes, vibration
perception, and monoﬁlament sensa-
tion. The “gold standard” for the diag-
nosis of DPN includes careful neurologic
examination to rule out other potential
causes of neuropathy and nerve conduc-
tion velocity studies. The Diabetes Con-
trol and Complications Trial (DCCT),
which used a combination of examina-
tion by a neurologist, nerve conduction
velocity testing, and autonomic neurop-
athy testing, clearly showed that im-
proved glycemic control reduced the
incidence of diabetic neuropathy, both
DPN and autonomic, by 44–60%.
However, most large prospective
studies have not been able to include
the gold standard of nerve conduction
studies and have utilized less invasive
and less expensive approaches to the
diagnosis of diabetic neuropathy. The
most commonly used is the Michigan
Neuropathy Screening Instrument
(MNSI). The MNSI is a self-administered
questionnaire (MNSIQ) and an examina-
tion (MNSIE) for foot abnormalities,
distal vibration perception, and ankle
reﬂexes; the MNSI has been validated
in adults with type 1 diabetes as a screen-
ing tool for neuropathy (166–169). It
should be noted, however, that the
MNSIE does not include an assessment
of small-ﬁber dysfunction.
Evidence of diabetic neuropathy using
the MNSI was found in 26% of youth with
type 2 diabetes in the SEARCH study (168)
and in 21% of an Australian cohort using
thermal (small ﬁber) and vibration (large
ﬁber) threshold testing (149). In addition,
more than half of the cohort had evi-
dence of autonomic neuropathy (pupil-
lary reactivity) after a median duration
of diabetes of 1.3 years (149). In an Indian
cohort ofmean age 16 years at diagnosis,
the prevalence of neuropathy increased
from 3% in those with diabetes dura-
tion ,5 years to 49% in those with
duration.15 years (170). In the SEARCH
study, the prevalence of abnormal MNSI
was signiﬁcantly higher in youth with
type 2 diabetes compared with those
with type 1 diabetes after adjustment for
age and sex. This association was no
longer signiﬁcant after adjustment for
the covariates of diabetes duration, waist
circumference, blood pressure, HDL cho-
lesterol, and microalbuminuria (168). In
the Australian cohort, the prevalence of
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peripheral and autonomic neuropathy in
adolescents with type 2 diabetes was
similar to that of the type 1 diabetes
cohort despite shorter diabetes duration
(1.3 vs. 6.8 years) and lowerA1C (7.3%vs.
8.5%) (149). In adolescents with type 1
diabetes, data fromtheDCCTsupport the
importance of intensive glycemic ther-
apy and reduction of A1C for the preven-
tion of diabetic neuropathy (171,172).
So far, such data do not exist in youth
with type 2 diabetes.
The ADA recommends that assess-
ment for symmetric DPN should in-
clude a careful history and assessment
of either temperature or pinprick sensa-
tion (small-ﬁber function) and vibration
sensation using a 128-Hz tuning fork (for
large-ﬁber function). All patients should
have annual 10-g monoﬁlament testing
to identify feet at risk for ulceration and
amputation (173). Since it appears that
youth with type 2 diabetes develop DPN
at least as frequently as adults, youth
with type 2 diabetes should be screened
at the same frequency: at diagnosis and
annually.
Retinopathy
Recommendations
c Screening for retinopathy should
be performed by dilated fundo-
scopy or retinal photography at
or soon after diagnosis and annu-
ally thereafter. C
c Optimizing glycemia is recom-
mended to decrease the risk or slow
the progression of retinopathy. B
c Less frequent examination (every
2 years) may be considered if there
is adequate glycemic control and a
normal eye exam. C
Diabetic retinopathy refers to changes
in the small vessels of the retina with the
occurrence of hemorrhages, microaneu-
rysms, exudates, or abnormal vessels. The
prevalence of retinopathy in youth with
type 2 diabetes is reported to be between
2% and 40%, depending on the method-
ology used, the age of the participants,
and the duration of diabetes. The prev-
alence is higher with greater duration
of the disease, although retinopa-
thy has been reported at diagnosis
(149,170,174). In the TODAY study, the
prevalence of early retinopathy by digital
fundus photography at a mean age of
18.1 years and mean duration of diabetes
of 4.9 years was 13.7%, with no evidence
of macular edema or proliferative reti-
nopathy (77). Retinopathy was associ-
ated with older age (19.1 vs. 17.9 years),
longer duration of diabetes (5.6 vs. 4.7
years), and higher A1C (8.3% vs. 6.9%).
Moreover, the odds ratio for retinopathy
increased with increasing A1C, age, and
duration of diabetes (77). In the SEARCH
study, the prevalence of retinopathy
using retinal photography was 42%
at a mean age of 21 years and mean
duration of type 2 diabetes of 7.2 years
(175). A1C and LDL cholesterol were
signiﬁcantly higher among those with
retinopathy compared with those with-
out. In Pima Indians, retinopathy was
detected only after age 20 years and only
after 5 years of diabetes duration (158).
However, by 30 years of age, retinopathy
had developed in 45% of this population
(158).
NAFLD
Recommendations
c Evaluation for NAFLD (by measur-
ing ALT and AST) should be done at
diagnosis of type 2 diabetes and
annually thereafter. B
c Referral to gastroenterology
should be considered for persis-
tently elevated or worsening trans-
aminases. B
The prevalence of dysglycemia in youth
with NAFLD is higher than in those
without NAFLD (176). In a multicenter
cohort of youth with NAFLD, primarily of
Hispanic descent, a third of the children
with NAFLD had abnormalities in glucose
metabolism; 23.4% had prediabetes and
6.5% had type 2 diabetes (176). More-
over, type 2 diabetes in youth is associ-
ated with greater NAFLD histologic
severity than in adults, which may
imply a heightened risk of progression
to ﬁbrosis, cirrhosis, and hepatic failure
(176,177). Therefore, it is particularly
important to evaluate forNAFLD in youth
with obesity and type 2 diabetes. For
screening, transaminase levels are a clin-
ical tool that is widely available and has a
good sensitivity for the detection of more
advanced stages of hepatitis or ﬁbrotic
changes, but these tests are not disease
speciﬁc; therefore, other causes of
chronic liver disease should be ruled
out (178,179). Recently, population-
based cutoffs lower than those used
in clinical laboratories have been advo-
cated to indicate abnormality (180).
Among the noninvasive diagnostic tests,
MRI/MRS are currently the preferred
imaging modalities, though of limited
clinical application (181). Liver ultra-
sound, though a widely available clini-
cal tool, is operator dependent and
detects liver fat .30% with sensitivity
of 80%, but sensitivity is lower with
lower degrees of fatty inﬁltration and
the presence of morbid obesity. Hence,
its value in the early diagnosis of NAFLD
is limited (181). Among the noninva-
sive modalities, elastography is useful
in evaluating advanced ﬁbrosis and cir-
rhosis (181) and is gaining wider accep-
tance. Liver biopsy remains the gold
standard for diagnosis and staging of
liver disease and the only way to differ-
entiate between nonalcoholic steato-
hepatitis and hepatic steatosis. Treatment
options for NAFLD remain limited, with
weight loss being most effective. Ther-
apeutic agents tested in randomized
clinical trials in youth includemetformin,
vitamin E, and cysteamine, with no clear
established beneﬁt on histologic out-
comes or sustained reduction in ALT
(182–184).
Obstructive Sleep Apnea
Recommendation
c Screening for symptoms of ob-
structive sleep apnea (OSA) should
be done at each visit, and referral
to a pediatric sleep specialist for
evaluation and a polysomnogram,
if indicated, is recommended. OSA
should be treated when docu-
mented. B
Sleep disturbance (insufﬁcient or dis-
rupted sleep, circadian rhythm dysreg-
ulation) and OSA are increasingly
recognized as being associated with
obesity (185–189), insulin resistance
in adults and children (52,190–195),
and type 2 diabetes in adults (196–
199), as well as risk for future CVD
(200). Experimental sleep restriction
results in decreased glucose clearance
and postprandial glucose elevation
(193,201), decrease in glucose effective-
ness, and variable decrease in insulin
sensitivity (190,192,202). OSA may in-
ﬂuence glycemic regulation in individ-
uals with diabetes; in adults with type
2 diabetes, treatment of OSA with
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continuous positive airway pressure has
been associated with improvement in
the glycemic proﬁle (203), decreased
A1C, and improvement in insulin sensi-
tivity indices (204) as well as inﬂamma-
tion (205) in some, but not all, studies.
Further study is needed.
Polycystic Ovary Syndrome
Recommendations
c Evaluate for polycystic ovary
syndrome (PCOS) in female ado-
lescents with type 2 diabetes, in-
cluding laboratory studies when
indicated. B
c Oral contraceptives for treatment
of PCOS are not contraindicated for
girls with type 2 diabetes. C
c Metformin in addition to lifestyle
modiﬁcation is likely to improve the
menstrual cyclicity and hyperan-
drogenism in girls with type 2 di-
abetes. E
PCOS affects 5–10% of females in the
reproductive age-group and is charac-
terized by hyperandrogenism and amen-
orrhea or oligomenorrhea secondary to
chronic anovulation (206,207). The prev-
alence of PCOS is signiﬁcantly higher in
adolescent girls with obesity compared
with adolescent girls without overweight/
obesity (208), but the prevalence in
adolescent girls with type 2 diabetes is
not well studied. Insulin resistance with
compensatory hyperinsulinemia are
metabolic features in both adult women
with PCOS with and without overweight/
obesity (209) and in adolescent girls with
PCOS compared with control subjects of
similar age, body composition, and ab-
dominal adiposity (210). In adolescent
girls with PCOS and obesity, this in-
creased insulin resistance when com-
bined with impaired b-cell function
predisposes to prediabetes and type 2
diabetes (211), with higher prevalence
of impaired glucose tolerance (30%) and
type 2 diabetes (3.7%) (212). Therefore,
it is important to obtain a menstrual
history and evaluate female adolescents
with type 2 diabetes for signs and symp-
toms of hyperandrogenism (irregular
menses, hirsutism, acne) and to initiate
appropriate diagnostic evaluation for
PCOS if indicated (213,214). In theTODAY
cohort, 21% of adolescent girls who
were $1-year postmenarche had irreg-
ular menses. Those with irregular menses
versus regular menses had higher total
testosterone, free androgen index, BMI,
and AST and lower sex hormone–binding
globulin and estradiol (215). Treatment
of PCOS in adolescents includes lifestyle
changes (216–218), the use of oral con-
traceptive pills (OCPs), and insulin sen-
sitizers, such as metformin (213).
However, the use of some OCPs has
been associated with unfavorable ef-
fects on indices of insulin sensitivity
(219) and lipid proﬁle (220). The use
of metformin therapy for 3–12 months
was associated with decrease in serum
androgens, improvement in lipid proﬁle,
induction of ovulation, and improvement
in glucose tolerance and insulin sensitiv-
ity (216,221,222). Therefore, in girls with
type 2 diabetes and PCOS, treatment
with metformin in addition to lifestyle
modiﬁcation is likely to improve the
metabolic dysfunction associated with
PCOS and may improve menstrual cy-
clicity and hyperandrogenism (213,218).
However, for the girls in the TODAY
study, all of whom received metformin,
there was no treatment group (met-
formin alone, metformin plus lifestyle,
and metformin plus rosiglitazone) ef-
fect on menses or sex steroids at 12
and 24 months and no association of sex
steroids with surrogate estimates of in-
sulin sensitivity or secretion (215). De-
spite the potential negative effects of
OCPs, which may not be shared by all
OCPs, on metabolic status and cardio-
vascular risk, hormonal contraceptive
therapy is more effective at addressing
the symptoms of hyperandrogenism
and anovulation and is not contrain-
dicated in female youth with type 2
diabetes (213).
CVD
Recommendation
c Intensive lifestyle interventions
focusing on weight loss, dyslipide-
mia, hypertension, and dysglyce-
mia are important to prevent overt
macrovascular disease in early
adulthood. E
Dyslipidemia
Recommendations
c Lipid testing should be performed
when initial glycemic control has
been achieved and annually there-
after. B
c Optimal cholesterol goals are LDL
,100 mg/dL (2.6 mmol/L), HDL
.35 mg/dL (0.905 mmol/L),
triglycerides ,150 mg/dL (1.7
mmol/L). E
c If LDL cholesterol is .130 mg/dL,
blood glucose control should be
maximized and dietary counsel-
ing should be provided using the
American Heart Association Step
2 diet. E
c If LDL cholesterol remains above
goal after 6 months of dietary in-
tervention, initiate therapy with
statin, with goal of LDL ,100
mg/dL. B
c If triglycerides are .400 mg/dL
(4.7 mmol/L) fasting or .1,000
mg/dL (11.6 mmol/L) nonfasting,
optimize glycemia and begin ﬁ-
brate, with a goal of ,400 mg/dL
(4.7 mmol/L) fasting (to reduce risk
for pancreatitis). C
Although there have been no long-
term studies of the outcome of
cholesterol-lowering therapy in youth
with type 2 diabetes, studies in youth
with familial hypercholesterolemia have
shown reduction in carotid intima-media
thickness (IMT) with the use of statins
(223,224), with similar efﬁcacy and side
effects as in adults. However, in a recent
multicenter, multinational study of youth
with type 1 diabetes, statin use did not
have a signiﬁcant effect on carotid IMT
despite reductions in total LDL choles-
terol and triglyceride concentrations
(225). Although longitudinal, interven-
tional data with statins in youth-onset
type 2 diabetes are not yet available,
statin therapy in youth with type 2 di-
abetes who do not meet LDL targets
following lifestyle change intervention
is considered a reasonable approach
and aligned with overall recommenda-
tions for dyslipidemia (226), given that
dyslipidemia in youth tracks into adult-
hood and is anticipated to confer in-
creased cardiovascular risk. Similarly,
though there have been no studies of
the use of ﬁbrates in youth with type 2
diabetes and hypertriglyceridemia to
prevent pancreatitis, extrapolation
from studies in adults supports the
use of these agents for severe hyper-
triglyceridemia in adolescents. Adoles-
cent girls treated with statins or ﬁbrates
should receive counseling on potential
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risk to the fetus and be encouraged to
use effective birth control.
Cardiac Function Testing
Recommendation
c Routine screening for heart disease
with electrocardiogram, echocar-
diogram, or stress testing is not
recommended in asymptomatic
youth with type 2 diabetes. B
Macrovascular disease involves coro-
nary, cerebral, and peripheral arterial
disease. In adults, type 2 diabetes is
associated with doubling of risk for
CVD, including coronary heart disease
and stroke as well as increased risk of
heart failure, after adjusting for age, sex,
smoking status, BMI, and systolic blood
pressure (227). Diabetes duration is im-
plicated as a major risk factor for CVD
(228,229), though there may also be a
worsened risk of CVD with early onset of
type 2 diabetes (228,230). While overt
cardiovascular events arenotexpected in
youth with type 2 diabetes, epidemio-
logical and clinical studies show that the
atherosclerotic process starts during
childhood (231), with strong relation-
ships between childhood obesity,
elevated blood pressure, low HDL cho-
lesterol, and coronary artery disease in
adulthood (232–235). Furthermore,
studies of vascular function have dem-
onstrated subclinical vascular disease in
adolescents with obesity and type 2 di-
abetes, including elevated aortic pulse
wave velocity, a marker of vascular stiff-
ness (236), and increased carotid IMT, a
structural measure of atherosclerosis,
compared with normoglycemic youth
with and without overweight/obesity
(237). In the SEARCH study, youth
with type 2 diabetes had worse arterial
stiffness than thosewith type 1 diabetes,
attributed to greater central adiposity
and hypertension but not related to
duration of diabetes or glycemic control
(238). In studies of obese youth with and
without type 2 diabetes, carotid IMT was
signiﬁcantly related to glycemia, while
aortic pulse wave velocity was related to
insulin resistance and inﬂammation
(239). In addition, total body and abdom-
inal adiposity were signiﬁcant determi-
nants of coronary artery calciﬁcations in
these youth (239). In TODAY, echocar-
diographic evaluation revealed a rela-
tionship of BMI and blood pressure
with adverse cardiac measures (240),
though there was a protective effect
of cardiorespiratory ﬁtness on functional
measures of cardiac structure and func-
tion in this group of largely sedentary
youth (241). Overall, studies to date
indicate signiﬁcant vascular dysfunction
and greater risk of progression to overt
CVD in youth with obesity and type 2
diabetes. The vascular dysfunction may
begin prior to the diagnosis of type 2
diabetes as a result of obesity and insulin
resistance.
In adults, type 2 diabetes is associated
with an increased risk of mortality, with
cardiac disease as amajor cause of death
(242); the excess mortality is related to
worse glycemic control, impaired renal
function, and younger age at diabetes
diagnosis (243). Youth-onset type 2 di-
abetes appears to be associated with an
earlier onset of complications and an
increased mortality risk compared with
type 1 diabetes (109,244,245). In a Swed-
ish study, type 2 diabetes diagnosed
between 15 and 34 years of age was
associated with a higher standardized
mortality ratio than type 1 diabetes
(2.9 and 1.8, respectively), with an in-
creased hazard ratio for males versus
females (P5 0.0002) (244). Similarly, an
epidemiological study from Australia
reported a signiﬁcant mortality excess
over 15–30 years of follow-up in individ-
uals diagnosed with type 2 diabetes
between 15 and 30 years of age com-
pared with type 1 diabetes, with a hazard
ratio of 2.0 (95% CI 1.2–3.2), despite
shorter average disease duration (26.9
vs. 36.5 years, P 5 0.01) and similar
glycemic control (109). The mortality
excess was related to an excess of car-
diovascular deaths in those with type 2
diabetes (50% vs. 30%, P, 0.05). In First
Nations individuals, increased mortality
with type 2 diabetes is reported in re-
lation to end-stage renal disease (159)
and is signiﬁcantly higher than in indi-
viduals with youth-onset type 1 diabetes
(245). In a large cohort of 354 patients
with type 2 diabetes diagnosed between
15 and 30 years of age compared with
a duration-matched cohort of 1,062
patients diagnosed between 40 and
50 years old, the negative effect of di-
abetes on morbidity (albuminuria and
neuropathy scores) and mortality was
greatest for those diagnosed at a young
age. Standardized mortality adjusting
for duration was highest, at any
chronological age, for those diagnosed
between 15 and 30 years of age (246).
Taken together, these data raise signif-
icant concern regarding the long-term
outcome of youth-onset type 2 diabetes
and support the importance of aggres-
sive management of glycemia and CVD
risk factors in these youth.
TRANSITIONING FROM PEDIATRIC
TO ADULT CARE
Recommendation
c Youth with type 2 diabetes should
be transferred to an adult-oriented
diabetes specialist when deemed
appropriate by the patient and
provider. E
The process of transferring the pedi-
atric patient to an adult health care
provider is a challenge that has only
recently received attention in the liter-
ature but is now recognized to be “im-
portant and should begin well before
patients are transferred” (247). Both the
Society for Adolescent Medicine (248)
and the American Academy of Pediatrics,
along with other associations (249), have
position statements related to transition
of care for those with chronic diseases
and special medical needs that empha-
size the importance of a gradual and
collaborative process starting a year or
longer before the actual transition is to
occur. Published literature on this sub-
ject recommends progressive implemen-
tation as eight developmentally linked
steps (250,251).
The ADA, in partnership with the other
organizations of the ADA Transitions
Working Group (252), developed posi-
tion statements in 2011 (252), in
2014 (253), and in 2018 (254). Even
for youth with type 1 diabetes, deﬁcien-
cies and gaps in the transition process
have been demonstrated in observa-
tional cross-sectional research. These
gaps are summarized in recent reviews
(250,252,255) and include minimal em-
pirical evidence about the best ap-
proaches, differences in the style and
approach to health care delivery be-
tween pediatric and adult health care
providers, lack of well-deﬁned criteria
of readiness for transition or tools to as-
sess readiness, gaps in health insurance
coverage, changing social structure as
adolescents enter young adulthood,
differences in learning styles of the patient
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and teaching styles of the provider, and
lack of health care provider training re-
lated to transition of care.
Despite the prevailing evidence of the
need for better transition of care, there
are no controlled studies of the effec-
tiveness of such programs in patients
with youth-onset type 2 diabetes. Pa-
tients with type 1 diabetes have reduced
dropout from medical care, increased
number of visits, and reduced pregnancy
loss, DKA, and severe hypoglycemia dur-
ing the transition period using a “navi-
gator” to assist young adults (18–30
years old) (256–258).
Since emerging adults with type 2 di-
abetes express similar concerns related
to transition from pediatric to adult
health care providers (259), the same
principles discussed above and steps to
facilitate transition that apply to those
with type 1 diabetes should be consid-
ered in type 2 diabetes.
CONCLUSIONS
Even though our knowledge of youth-
onset type 2 diabetes has increased
tremendously over the last two decades,
robust and evidence-based data are still
limited regarding diagnostic and thera-
peutic approaches and prevention of
complications. The current-day informa-
tion indicates that there are fundamen-
tal differences in insulin sensitivity and
b-cell function between youth and adults
with prediabetes and type 2 diabetes,
which could possibly explain why some
youth develop type 2 diabetes decades
earlier than adults (23,24,260,261).
Youth are more insulin resistant and
have b-cells that are hyperresponsive
to stimulation compared with adults
(23,24,260,261). Puberty-related physio-
logic insulin resistance, particularly in
obese youth, may play a role in this
heightened insulin resistance. It remains
anenigma, though,why some individuals
with youth-onset type 2 diabetes dem-
onstrate durable control and others do
not (74). Furthermore, type 2 diabetes
appears to be more aggressive in youth
than adults, with a faster rate of de-
terioration of b-cell function (76) and
poorer response to glucose-lowering
medications (104). Future research
should probe the mechanisms responsi-
ble for this youth–adult contrast in the
various aspects of type 2 diabetes. Lastly,
complications in youth with type 2
diabetes appear early, resulting in higher
rates of morbidity and mortality com-
pared with type 1 diabetes. Preexisting
obesity and its comorbidities might play
a key role in amplifying the complica-
tions of youth-onset type 2 diabetes.
Intervention/prevention strategies for
type 2 diabetes should not be limited to
youth with dysglycemia only, but youth
with obesity at large.
In closing, the present guidelines
are based on current data, experi-
ence, opinion, and gained “wisdom.”
However, we anticipate that future
guidelines will change as more scientiﬁc
data emerge to support evidence-based
recommendations.
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